跳至主要内容
临床试验/NCT01347801
NCT01347801已完成不适用

Mechanisms of Insulin Resistance in Critical Illness: Role of Systemic Inflammation and GLP-1

Rigshospitalet, Denmark2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2011年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
40
试验地点
2
主要终点
Substudy 2C (12 Healthy volunteers): GLP-1

研究概览

简要总结

The purpose of this study is to determine the role of inflammation and the insulin regulating hormone GLP-1 during critical illness.

详细描述

Critically ill patients often exhibit hyperglycaemia. Although the cause of this hyperglycaemia is probably multifactorial, peripheral insulin resistance is a major contributor, similar to type 2 diabetes mellitus (T2D). There are several similarities between critical illness and T2D, including the presence of systemic inflammation and increased plasma free fatty acids (FFA), all of which may induce insulin resistance in healthy volunteers. In critical illness, elevated catecholamines, cortisol, growth hormone and glucagon may also contribute to insulin resistance.

The degree of hyperglycaemia correlates with mortality in ICU patients. van den Berghe et al. found that IV infusion of insulin to obtain strict normoglycaemia reduced mortality as well as morbidity in critically ill surgical patients and in some medical ICU patients.

However, insulin increases the risk of hypoglycaemia; this is a major obstacle to strict euglycaemia in ICU patients and may explain the inability of others to reproduce the benefits reported by van den Berghe et al. Thus, alternatives to insulin for controlling plasma glucose (PG) in ICU patients are warranted.

Aim:

To study the role of the incretin hormone, glucagon-like peptide (GLP)-1 for glycaemic, metabolic, hormonal and inflammatory profile in

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

2A-3

Active Comparator

TNF and OGTT

干预措施: OGTT (Other)

2C - 1

Placebo Comparator

TNF and OGTT and saline

干预措施: Placebo (Saline) (Drug)

2C - 1

Placebo Comparator

TNF and OGTT and saline

干预措施: TNF-alfa (Drug)

2C - 1

Placebo Comparator

TNF and OGTT and saline

干预措施: OGTT (Other)

2C - 2

Active Comparator

TNF and OGTT and GLP-1

干预措施: TNF-alfa (Drug)

2C - 2

Active Comparator

TNF and OGTT and GLP-1

干预措施: OGTT (Other)

2C - 3

Placebo Comparator

TNF and IVGTT and saline

干预措施: Placebo (Saline) (Drug)

2C - 3

Placebo Comparator

TNF and IVGTT and saline

干预措施: TNF-alfa (Drug)

2C - 3

Placebo Comparator

TNF and IVGTT and saline

干预措施: IVGTT (Other)

2C - 4

Active Comparator

TNF and IVGTT and GLP-1

干预措施: TNF-alfa (Drug)

2C - 4

Active Comparator

TNF and IVGTT and GLP-1

干预措施: IVGTT (Other)

2A-1

Placebo Comparator

Saline infusion and OGTT

干预措施: Placebo (Saline) (Drug)

2A-1

Placebo Comparator

Saline infusion and OGTT

干预措施: OGTT (Other)

2A-2

Placebo Comparator

Saline and IVGTT

干预措施: Placebo (Saline) (Drug)

2A-2

Placebo Comparator

Saline and IVGTT

干预措施: IVGTT (Other)

2A-3

Active Comparator

TNF and OGTT

干预措施: TNF-alfa (Drug)

2A-4

Active Comparator

TNF and IVGTT

干预措施: TNF-alfa (Drug)

2A-4

Active Comparator

TNF and IVGTT

干预措施: IVGTT (Other)

1C

Experimental

OGTT and corresponding IVGTT

干预措施: OGTT (Other)

1C

Experimental

OGTT and corresponding IVGTT

干预措施: IVGTT (Other)

2C - 4

Active Comparator

TNF and IVGTT and GLP-1

干预措施: GLP-1 (Drug)

2C - 2

Active Comparator

TNF and OGTT and GLP-1

干预措施: GLP-1 (Drug)

结局指标

主要结局

Substudy 2C (12 Healthy volunteers): GLP-1

时间窗: 6 weeks after intervention

Increased plasma insulin and C-peptide (intact insulinotropic effect of GLP-1) during GLP-1 infusion in healthy volunteers.

Substudy 2A (12 Healthy volunteers): Insulin, C-peptide and incretin hormone response

时间窗: 6 weeks after intervention

Insulin, c-peptide and incretin hormone response to glucose stimulation during standardized systemic inflammation (TNF infusion) compared to placebo (saline infusion)

Substudy 1C(8 patients, 8 healthy controls): Insulin, C-peptide and incretin hormone response

时间窗: 6 weeks after intervention

Insulin, c-peptide and incretin hormone response to glucose stimulation during IVGTT compared to OGTT in critically ill patients admitted to the ICU

次要结局

  • Substudy 2C (12 Healthy volunteers): Clamp(6 weeks after intervention)
  • Substudy 2A (12 Healthy volunteers): The incretin effect(6 weeks after intervention)
  • Substudy 1C (8 patients, 8 healthy controls): The incretin effect(6 weeks after intervention)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Kirsten Moller

MD, PH.D, DMSc

Rigshospitalet, Denmark

研究点 (2)

Loading locations...

相似试验

Mechanisms of Insulin Resistance in Critical... | 临床试验